Hard end-points for GH replacement therapy: report from an interactive discussion of bone status and cardiovascular function in GH-deficient adults.
To stimulate debate and promote interaction between the audience and speakers, an interactive session entitled "Controversies in GH Replacement Therapy" was held at the 4th International hGH Symposium on GH Deficiency in Adults in September 1997 in Copenhagen, Denmark. The audience was asked to vote "yes" or "no" to a number of questions pertaining to the effects of growth hormone (GH) substitution in GH deficiency in adults on bone and cardiovascular function, respectively. This was followed by "pro" and "con" presentations on GH after which the audience gave their second and final vote (answer) to the initial questions. The designated "pro" and "con" speakers were selected on the basis of their scientific contributions within the relevant field rather than their personal beliefs. This is a report of the interactive session.
Jørgensen
J O
JO
Medical Department M (Endocrinology and Metabolism), Aarhus University Hospital, Denmark.
D000328:Adult; D017668:Age of Onset; D001847:Bone Diseases / Q000150:complications; D001842:Bone and Bones / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000150:complications / Q000401:mortality; D002319:Cardiovascular System / Q000187:drug effects; D007722:Health Knowledge, Attitudes, Practice; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D011994:Recombinant Proteins; D019382:Human Growth Hormone